| Vincent Ossipow |
Vincent Ossipow is the founder and Chief Scientific Officer at Omega Alpha SPAC, which was founded in 2020. He is currently a Director at BioInvent International AB since 2016, eTheRNA immunotherapies NV since 2016, FoRx Therapeutics AG since 2019, and NeoMed S.Ã .r.l. since 2017. He is also an Independent Non-Executive Director at SOPHiA GENETICS SA since 2014 and a Director at Aerium Therapeutics, Inc. He is a Partner at Omega Fund Management LLC since 2014 and a Member-Supervisory Board at Immunic AG. Dr. Ossipow has held former positions as a Director at Lifespan, Inc., RainDance Technologies, Inc., Vital Therapies, Inc., and Kuros Biosciences Ltd. from 2015 to 2016. He was also a Director at Andrew Alliance SA and Luxe Trading SA. Dr. Ossipow served as an Independent Director at Immunic, Inc. from 2016 to 2023. He was a Partner at Omega Funds and a Co-Manager at Pictet - Biotech. He worked as an Investment Manager at Sectoral Asset Management, Inc. (Switzerland) from 2010 to 2013 and as a Partner & Financial Advisor at Covalence SA (Switzerland). Dr. Ossipow started his career as a Research Analyst at Pictet Bank & Trust Ltd. (Private Banking). He holds graduate and doctorate degrees from the University of Geneva. |
| Otello Stampacchia |
Otello Stampacchia is the founder of Omega Fund Management LLC, founded in 2004, and Omega Alpha SPAC, founded in 2020. He is currently the Chairman of Aerium Therapeutics, Inc. and a Director at Scorpion Therapeutics, Inc., Photys Therapeutics, Inc., Amunix Pharmaceuticals, Inc., Ikena Oncology, Inc., Morphic Therapeutic, Inc., and Rectify Pharmaceuticals LLC. Dr. Stampacchia has held former positions as a Director at SpineVision SA, CropDesign NV, Paratek Pharmaceuticals, Inc., ESSA Pharma, Inc., Translate Bio, Inc., Kronos Bio, Inc., Nuvation Bio Operating Co., Inc., Trident Pharmaceuticals, Inc., Exonhit, MEDIAN Technologies SA, Trevi Therapeutics, Inc., FibroGen, Inc., DeveloGen AG, Intarcia Therapeutics, Inc., Gossamer Bio, Inc., Andrew Alliance SA, Morphic Holding, Inc., BioVex, Inc., Replimune Group, Inc., Juno Therapeutics, Inc., Achaogen, Inc., Micromet AG, AlpInvest Partners BV, and LODH Immunology Fund. He was also an Associate at The Goldman Sachs Group, Inc. from 1996 to 2000. Dr. Stampacchia received a graduate degree from the University of Pavia in 1996 and a doctorate degree from the University of Geneva in 1996. |
| Michelle Doig |
Michelle joined Omega Funds in 2016. She has over 20 years of experience advising life sciences companies on private placements, public equity financing and M&A transactions. Michelle currently serves on the Board of Directors of Artios Pharma and is a board observer at Arrakis Therapeutics.
Previously, Michelle was Director of Corporate Finance at Third Rock Ventures, where she supported numerous portfolio companies through their initial private and public financings. Prior to joining Third Rock, Michelle was a Principal at Abingworth in London and Boston. She was also a life sciences investment banker with Lehman Brothers International in London, JP Morgan/H&Q in New York and Morgan Stanley in Toronto and New York. Michelle has executed more than 50 equity and convertible transactions and numerous IPOs, private placements and M&A transactions for companies, including Gilead, MedImmune, Millennium, Illumina and Sepracor. Michelle graduated with an Honor’s degree in Business Administration from the Richard Ivey School of Business at the University of Western Ontario in London. |
| Daniel S. Lynch |
Daniel S. Lynch's current job(s) include being the Executive Chairman at SpringWorks Therapeutics LLC since 2017, the Chairman at Springworks Therapeutics, Inc. since 2016, a Director at Alpha-Omega Cos., Inc., an Independent Director at Omega Alpha SPAC since 2021, and an Executive Venture Partner at GV Management Co. LLC since 2021. Mr. Lynch's former job(s) include being the President & Chief Executive Officer at Ivrea Pharmaceuticals, Inc., the Chairman at DNIB Unwind, Inc. from 2012 to 2016, the Chairman at Stromedix, Inc. from 2007 to 2012, the Executive Chairman at Proclara Biosciences, Inc., the Executive Chairman at Nimbus Therapeutics LLC from 2012 to 2015, the Chairman at Translate Bio, Inc. from 2012 to 2021, the Chairman at bluebird bio, Inc. from 2011 to 2021, the Executive Chairman at Avila Therapeutics, Inc. from 2008 to 2012, the Executive Chairman at Blueprint Medicines Corp. from 2012 to 2021, the Executive Chairman at Surface Oncology, Inc. from 2016 to 2021, the Chairman at Xilio Therapeutics, Inc. from 2020 to 2022, the Executive Chairman at eGenesis, Inc., a Director at US Oncology, Inc. from 2006 to 2010, a Director at US Oncology Holdings, Inc., a Director at Edimer Pharmaceuticals, Inc. from 2011 to 2013, an Independent Director at Sesen Bio, Inc. from 2013 to 2020, a Director at Ember Therapeutics, Inc. from 2011 to 2013, a Director at The Brain Injury Network of Dallas from 2012 to 2016, and a Director at 2seventy Bio, Inc. from 2021 to 2024. Mr. Lynch's education history includes an undergraduate degree from Wesleyan University in 1980 and an MBA from the University of Virginia Darden School of Business in 1984. |
| Jan G. J. van de Winkel |
Jan G. J. van de Winkel is the founder and currently holds the position of President & Chief Executive Officer at Genmab A, a company founded in 1999. He is also currently serving as Chairman-Supervisory Board at Regenesance BV, Chairman-Supervisory Director at Hookipa Biotech AG, Chairman at HOOKIPA Pharma, Inc., Director at LEO Pharma A, Director at Leo Pharma, Inc., and Independent Director at Omega Alpha SPAC. In his former positions, Dr. van de Winkel served as Vice President & Scientific Director at Medarex, Inc. and Medarex Europe BV, Director at Forward Pharma A from 2014 to 2017, Director at Celdara Medical LLC, Member at BTF Pty Ltd., and Member-Supervisory Board at ISA Pharmaceuticals BV. Dr. van de Winkel's education includes undergraduate and graduate degrees from the University of Utrecht, as well as a graduate and doctorate degree from Radboud University Nijmegen. |
| Martin Babler |
Martin Babler is currently the Chairman, President & Chief Executive Officer at Alumis, Inc. He is also a Director at the Biotechnology Innovation Organization, Prelude Therapeutics, Inc., Omega Alpha SPAC, Sardona Therapeutics, Inc., and 89bio, Inc. In the past, Mr. Babler served as the President & Chief Executive Officer at Talima Therapeutics, Inc. from 2010 to 2011. He was also the President, Chief Executive Officer & Director at Principia Biopharma, Inc. from 2019 to 2020. Additionally, he held the position of Vice President-Immunology Sales & Marketing at Genentech, Inc. from 2006 to 2007 and worked as a Principal at Eli Lilly & Co. from 1991 to 1998. |
